• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

    2/13/24 4:30:00 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVIR alert in real time by email
    SC 13G/A 1 d778503dsc13ga.htm SC 13G/A SC 13G/A

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

     

    Atea Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001

    (Title of Class of Securities)

    04683R106

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     


    CUSIP No. 04683R106    Schedule 13G    Page 1 of 7

     

     1   

     Names of Reporting Persons

     

     JPM Partners LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

     Sole Voting Power

     

     0

       6   

     Shared Voting Power

     

     5,925,000

       7   

     Sole Dispositive Power

     

     0

       8   

     Shared Dispositive Power

     

     5,925,000

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,925,000

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     7.1%

    12  

     Type of Reporting Person

     

     OO (Limited Liability Company)


    CUSIP No. 04683R106    Schedule 13G    Page 2 of 7

     

     1   

     Names of Reporting Persons

     

     Jean-Pierre Sommadossi

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

     Sole Voting Power

     

     2,237,914

       6   

     Shared Voting Power

     

     5,925,000

       7   

     Sole Dispositive Power

     

     2,237,914

       8   

     Shared Dispositive Power

     

     5,925,000

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,162,914

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     9.6%

    12  

     Type of Reporting Person

     

     IN


    CUSIP No. 04683R106    Schedule 13G    Page 3 of 7

     

    ITEM 1. (a)

    Name of Issuer:

    Atea Pharmaceuticals, Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    225 Franklin Street, Suite 2100, Boston, MA 02110.

     

    ITEM 2. (a)

    Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    JPM Partners LLC; and

    Jean-Pierre Sommadossi

     

      (b)

    Address or Principal Business Office:

    The business address of JPM Partners LLC is 2 Avery Street #21E, Boston, MA 02111. The business address of Dr. Sommadossi is c/o Atea Pharmaceuticals, Inc., 225 Franklin Street, Suite 2100, Boston, MA 02110.

     

      (c)

    Citizenship:

    JPM Partners LLC is a Delaware limited liability company. Dr. Sommadossi is a citizen of the United States.

     

      (d)

    Title of Class of Securities:

    Common stock, par value $0.001 per share (“Common Stock”).

     

      (e)

    CUSIP Number:

    04683R106

     

    ITEM 3.

    Not applicable.


    CUSIP No. 04683R106    Schedule 13G    Page 4 of 7

     

    ITEM 4.

    Ownership.

    The ownership information below represents beneficial ownership of shares of Common Stock as of the date hereof, based upon 83,435,513 shares of Common Stock outstanding as of November 7, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

    (a-c)

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

       

    Sole

    power
    to vote

    or to

    direct

    the vote:

         Shared
    power to
    vote or to
    direct the
    vote:
        

    Sole

    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    JPM Partners LLC

         5,925,000        7.1 %      0        5,925,000        0        5,925,000  

    Jean-Pierre Sommadossi

         8,162,914        9.6 %      2,237,914        5,925,000        2,237,914        5,925,000  

    JPM Partners LLC is the record holder of 5,925,000 shares of Common Stock. Dr. Sommadossi is the manager of JPM Partners LLC and may be deemed to share beneficial ownership of the securities held by JPM Partner LLC. In addition, Dr. Sommadossi beneficially owns 2,237,914 shares of Common Stock, which includes 2,121,357 shares of Common Stock subject to stock options that are currently exercisable or will become exercisable within 60 days of the date hereof.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.


    CUSIP No. 04683R106    Schedule 13G    Page 5 of 7

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. 04683R106    Schedule 13G    Page 6 of 7

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 13, 2024

     

    JPM Partners LLC
    By:  

    /s/ Jean-Pierre Sommadossi

    Name: Jean-Pierre Sommadossi
    Title: Manager
    Jean-Pierre Sommadossi

    /s/ Jean-Pierre Sommadossi


    CUSIP No. 04683R106    Schedule 13G    Page 7 of 7

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $AVIR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVIR

    DatePrice TargetRatingAnalyst
    8/13/2024$2.00 → $6.88Underweight → Equal-Weight
    Morgan Stanley
    8/10/2023Neutral → Underweight
    JP Morgan
    3/2/2022$10.00 → $8.00Neutral
    JP Morgan
    3/1/2022$10.00 → $9.00Market Perform
    SVB Leerink
    2/16/2022$11.00 → $10.00Market Perform
    SVB Leerink
    1/6/2022$14.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    11/18/2021Outperform → Mkt Perform
    SVB Leerink
    11/18/2021$11.00Outperform → Market Perform
    SVB Leerink
    More analyst ratings